We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings.
- Authors
Andrey, Diego O.; Yerly, Sabine; Meyer, Benjamin; Arm-Vernez, Isabelle; Roux-Lombard, Pascale; Togni, Giuseppe; Guessous, Idris; Spechbach, Hervé; Stringhini, Silvia; Agoritsas, Thomas; Stirnemann, Jérôme; Reny, Jean-Luc; Siegrist, Claire-Anne; Eckerle, Isabella; Kaiser, Laurent; Vuilleumier, Nicolas
- Abstract
Purpose: To assess the diagnostic performances of five automated anti-SARS-CoV-2 immunoassays, Epitope (N), Diasorin (S1/S2), Euroimmun (S1), Roche N (N), and Roche S (S-RBD), and to provide a testing strategy based on pre-test probability. Methods: We assessed the receiver operating characteristic (ROC) areas under the curve (AUC) values, along with the sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs), of each assay using a validation sample set of 172 COVID-19 sera and 185 negative controls against a validated S1-immunofluorescence as a reference method. The three assays displaying the highest AUCs were selected for further serodetection of 2033 sera of a large population-based cohort. Results: In the validation analysis (pre-test probability: 48.1%), Roche N, Roche S and Euroimmun showed the highest discriminant accuracy (AUCs: 0.99, 0.98, and 0.98) with PPVs and NPVs above 96% and 94%, respectively. In the population-based cohort (pre-test probability: 6.2%) these three assays displayed AUCs above 0.97 and PPVs and NPVs above 90.5% and 99.4%, respectively. A sequential strategy using an anti-S assay as screening test and an anti-N as confirmatory assays resulted in a 96.7% PPV and 99.5% NPV, respectively. Conclusions: Euroimmun and both Roche assays performed equally well in high pre-test probability settings. At a lower prevalence, sequentially combining anti-S and anti-N assays resulted in the optimal trade-off between diagnostic performances and operational considerations.
- Subjects
SARS-CoV-2; IMMUNOASSAY; SEROLOGY; RECEIVER operating characteristic curves; COVID-19
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 8, p1605
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10081605